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Key points
 Increased activation of the renin-angiotensin-aldosterone system (RAAS) and elevated growth
factor production are of crucial importance in the development of renal fibrosis leading to
diabetic kidney disease.
 The aim of this study was to provide evidence for the antifibrotic potential of RAAS inhibitor
(RAASi) treatment and to explore the exact mechanism of this protective effect.
 We found that RAASi ameliorate diabetes-induced renal interstitial fibrosis and decrease
profibrotic growth factor production.
 RAASi prevents fibrosis by acting directly on proximal tubular cells, and inhibits
hyperglycaemia-induced growth factor production and thereby fibroblast activation.
 These results suggest a novel therapeutic indication and potential of RAASi in the treatment of
renal fibrosis.
Abstract In diabetic kidney disease (DKD) increased activationof renin-angiotensin-aldosterone
system (RAAS) contributes to renal fibrosis. Although RAAS inhibitors (RAASi) are the gold
standard therapy in DKD, the mechanism of their antifibrotic effect is not yet clarified. Here we
tested the antifibrotic and renoprotective actionofRAASi in a ratmodel of streptozotocin-induced
DKD. In vitro studies on proximal tubular cells and renal fibroblasts were also performed to
further clarify the signal transduction pathways that are directly altered by hyperglycaemia.
After 5 weeks of diabetes, male Wistar rats were treated for two more weeks per os with the
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RAASi ramipril, losartan, spironolactone or eplerenone. Proximal tubular cells were cultured
in normal or high glucose (HG) medium and treated with RAASi. Platelet-derived growth
factor (PDGF) or connective tissue growth factor (CTGF/CCN2)-induced renal fibroblasts
were also treated with various RAASi. In diabetic rats, reduced renal function and interstitial
fibrosis were ameliorated and elevated renal profibrotic factors (TGFβ1, PDGF, CTGF/CCN2,
MMP2, TIMP1) and alpha-smooth muscle actin (αSMA) levels were decreased by RAASi. HG
increased growth factor production of HK-2 cells, which in turn induced activation and αSMA
production of fibroblasts. RAASi decreased tubular PDGF and CTGF expression and reduced
production of extracellular matrix (ECM) components in fibroblasts. In proximal tubular cells,
hyperglycaemia-induced growth factor production increased renal fibroblast transformation,
contributing to the development of fibrosis. RAASi, even innon-antihypertensive doses, decreased
the productionof profibrotic factors anddirectly preventedfibroblast activation.All these findings
suggest a novel therapeutic role for RAASi in the treatment of renal fibrosis.
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Introduction
Diabetes mellitus (DM) is a major health concern,
impairing the quality of life and diminishing the life
expectancy of millions of people (International Diabetes
Federation, 2017). Diabetic kidney disease (DKD) affects
more than 20% of all diabetic patients, and due to
limited therapeutic options it remains the leading cause of
chronic kidney disease (CKD) (Saran et al. 2018). Current
treatment strategies may hinder kidney injury, but are
unable to stop the progression into CKD (Solis-Herrera
et al. 2014). Therefore, a better understanding of the
molecular mechanisms involved in the pathophysiology
of DKD is needed in the research for novel therapeutic
concepts.
The progression of DKD is caused by haemodynamic
andmetabolic changes leading to structural and functional
alterations. Structural changes, starting with glomerular
basement membrane thickening and mesangial matrix
expansion, gradually progress into glomerulosclerosis
and interstitial fibrosis, and result in glomerular hyper-
filtration and microalbuminuria (Tervaert et al. 2010).
Chronic and uncontrolled hyperglycaemia increases
the production of several profibrotic factors such as
transforming growth factor β (TGFβ), platelet-derived
growth factor (PDGF), and connective tissue growth
factor/CCN family (cysteine-rich 61, connective tissue
growth factor, nephroblastoma overexpressed) member
2 (CTGF/CCN2), and contributes to fibrotic connective
tissue accumulation characterised by elevated fibronectin
and collagen levels (Garud & Kulkarni, 2014). Fibroblasts
are the main effector cells of fibrosis and their activation
is indicated by alpha-smooth muscle actin (αSMA)
production. When activated, they serve as primary
collagen-producing cells and contribute to extracellular
matrix (ECM) accumulation (Wynn, 2008). In this
state the balance of ECM dynamics is disturbed as the
rate of production exceeds the rate of degradation and
therefore ECM components such as type I and type
III collagen, fibronectin and matrix metalloproteinases
(MMPs) accumulate (Kolset et al. 2012).
The formation and degradation of ECM components
lead to specific pro-collagen terminal fragments and
protein neo-epitopes secreted into urine (Genovese et al.
2014), which have recently been discovered as novel, early
urinary biomarkers of renal fibrosis. Two of them are
neo-epitopes of MMP-9-mediated degradation of type
III collagen (C3M) and type IV collagen alpha 3 chain
known as tumstatin (TUM) (Genovese et al. 2016; Nielsen
et al. 2018). Numerous recent studies have confirmed the
association of urinary C3M (uC3M) with renal fibrosis
in different rat models including 5/6 Nx, anti-Thy 1.1,
adenine nephropathy and type 2 diabetic nephropathy
models (Papasotiriou et al. 2015; Dower et al. 2017). In a
proteinuria-driven rat model, uC3M levels were elevated
andmeasurable even before being histologically detectable
(Hijmans et al.2017). In type 1diabetes thesemarkers have
not been tested yet and the effect of RAASi treatment on
their excretion has not been investigated either.
Until recently glomeruli were considered to be the
primary sites of DKD, but an increasing body of evidence
shows that hyperglycaemia-induced tubulointerstitial
lesions have a prominent causative role as well. Hyper-
glycaemia increases tubular glucose load and leads
to tubular hyperplasia and hypertrophy through early
functional changes like primary proximal tubular hyper-
reabsorption. Increased DNA synthesis induces the trans-
ition to senescencewhere local pro-inflammatory cytokine
release, growth factor production and ECM components
form a basis of tubulointerstitial fibrosis (Vallon, 2011).
Available therapeutic strategies are inefficient in pre-
venting the progression of kidney injury (Karihaloo,
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2012), and therefore novel treatment options are definitely
needed.
Several studies demonstrate that various RAASi
effectively decrease renal functional and structural damage
in DM (Mifsud et al. 2001; Osicka et al. 2001; Gellai
et al. 2016). Some of these highlight the exceptional role
of aldosterone antagonists (Taira et al. 2008; Banki et al.
2012), although the molecular pathways involved in their
renoprotective effect are still not fully understood.
The aim of the present study was to understand the
underlying mechanisms involved in DM-induced renal
fibrosis and to investigate the potential antifibrotic effect
of RAASi. Furthermore, the effects of RAASi on proximal
tubular epithelial cells and on renal fibroblasts were
studied to explore their direct renoprotective potential.
Methods
Ethical approval
All animal procedures were approved by the Committee
on the Care and Use of Laboratory Animals of the
Council on Animal Care at Semmelweis University,
Budapest,Hungary (PEI/001/380-4/2013) and conform to
the principles and regulations of The Journal of Physiology.
The investigators state their confirmation of compliance
with the ethical principles under which The Journal of
Physiology operates and that our work complies with its
animal ethics checklist.
Materials
All chemicals were purchased from Sigma-Aldrich
(Darmstadt, Germany) unless stated otherwise, and all
standard plastic laboratory equipment was purchased
from Sarstedt (Nu¨mbrecht, Germany).
Animals, induction of diabetes and experimental
groups
Six-week-old male Wistar rats (Rattus norvegicus,
RGD Cat. No. 13508588, RRID:RGD 13508588) were
purchased from “Toxi-Coop” Toxicological Research
Centre (Dunakeszi, Hungary) and kept in plastic cages
under 12-hour dark/light cycle at constant temperature
(24 ± 0.2°C) with ad libitum access to standard rodent
chow and drinking water. Diabetes was induced with a
single I.P. injection of 65mg (kg bodywt)−1 streptozotocin
(STZ), dissolved in 0.1 M citrate buffer (pH 4.5). Blood
glucose levels were measured three times from the tail
vein after an overnight fast with a D-Cont IDEAL
device (77Elektronika, Budapest,Hungary).Animalswere
considered diabetic if peripheral blood glucose level was
above 15 mmol L−1 72 h after the STZ injection and
remained elevated. Five weeks after the induction of
diabetes rats were randomised into five groups (n = 7–8
animals/group) and were treated daily by oral gavage for
2 weeks either with: (i) isotonic saline as vehicle (D); or
(ii) ramipril (D + ramipril, 10 μg (kg body wt)−1 day−1);
losartan (D + losartan, 20 mg (kg body wt)−1 day−1);
spironolactone (D + spironolactone, 50 mg (kg body
wt)−1 day−1) or eplerenone (D + eplerenone, 50 mg (kg
bodywt)−1 day−1). Doseswere adopted fromour previous
studies in line with literary data where effective blockade
of angiotensin-converting enzyme (ACE), angiotensin II
receptor 1 (AT1) or aldosterone activity was achieved
without changes in systemic blood pressure (Taira et al.
2008; Failli et al. 2009; Banki et al. 2012). Non-diabetic,
age-matched animals (control; n = 8 animals/group)
received equivalent volumes of citrate buffer without
STZ once, and the same amount of saline by oral
gavage daily, at the same time as the diabetic animals
throughout the 2-week treatment period. At the end of the
experimental protocol ratswere anaesthetisedby amixture
of 75 mg (kg body wt)−1 ketamine (Richter Gedeon,
Budapest, Hungary) and 10 mg (kg body wt)−1 xylazine
(Medicus Partner, Biatorbagy,Hungary) administered I.P.,
after which breathing and cardiac function decreased and
terminal blood was drawn from the abdominal aorta to
kill the animals. Blood, urine and kidney samples were
collected and stored for further investigations.
Arterial blood pressure
Systolic and diastolic blood pressures were measured
on the tail vein and mean arterial pressure was
calculated using a CODA tail cuff standard monitoring
system (EMKA Technologies, Paris, France), which
uses proprietary volume pressure recording, a clinically
validated technology (Kurtz et al. 2005).
Metabolic and renal parameters
Body and kidney weights were measured, and kidney-to-
bodyweight ratio and creatinine clearancewere calculated.
Serummetabolic (glucose, fructosamine) and renal (blood
urea nitrogen, creatinine) parameters were determined
with commercially available kits on a Hitachi 912
chemistry analyser (Roche Hitachi, Basel, Switzerland).
Renal histology and morphometric analysis
Kidneys were fixed in 4% buffered formalin, embedded in
paraffin and 5 μm thick sections were taken.
Glomerular hypertrophy was determined in periodic
acid-Schiff (PAS)-stained sections as previously described
(Degrell et al. 2009) by measuring 20 glomerular tuft
areas at 400× magnification from each animal, excluding
incomplete glomeruli along the sample edge. The number
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of pixels containing purple mesangial matrix deposition
was divided by the total number of pixels in the
glomerulus to obtain the percentage area of mesangial
matrix deposition.
Tubulointerstitial fibrosis was evaluated in Masson’s
trichrome-stained sections and Picrosirius Red staining
was performed for supplemental fibrosis. Ten areas at
200× (Masson’s) or 100× (Picrosirius) magnification
from each kidney cross-section were randomly selected
and specifically stained interstitial areas were measured.
The number of pixels containing stainedfibrotic tissuewas
divided by the total number of pixels in the area to obtain
the percentage of tubulointerstitial fibrosis and collagen
deposition.
Areas were measured with Panoramic Viewer software
version 1.15.2 (3DHISTECH, RRID: SCR 016296).
Analysis was performed in a double blinded fashion with
computer-assisted morphometry using Adobe Photo-
shop CS6 (Adobe Systems, RRID:SCR 014199) and Scion
Image software version 1.49 (National Institutes ofHealth,
RRID:SCR 008673).
Cell cultures and treatments
Human kidney 2 proximal tubular epithelial (HK-2)
cells (LGC Standards, ATCC Cat. No. CRL-2190,
RRID:CVCL 0302) were cultured in DMEM containing
5.5 mM glucose (Gibco, supplied by Life Technologies,
Carlsbad, CA, USA) and normal rat kidney fibroblast
(NRK-49F) cells (LGC Standards, ATCC Cat. No.
CRL-1570, RRID:CVCL 2144) were maintained in
DMEM containing 25 mM glucose (Gibco), both
supplemented with 10% FBS (Gibco), 1% penicillin/
streptomycin and 1% L-glutamine, and incubated at 5%
CO2 and 37°C. Before the treatments,HK-2 andNRK-49F
cells were plated in 6-well plates (5 × 105 cells/well)
for 24 h in serum-free medium. In the case of HK-2
cells, the medium was changed and cells were kept
under normal (control; 5.5 mM) or high glucose (HG;
35 mM) conditions for 24 h. HG groups were treated
with either 10 μM ramipril (HG + ramipril), or 10 μM
losartan (HG + losartan), or 200 nM spironolactone
(HG + spironolactone), or 10 μM eplerenone (HG +
eplerenone). Control cells were treated with vehicle
(DMSO) alone (n = 6 wells/group). Drug doses were
adopted from the literature (Oroszlan et al. 2010;
Wei et al. 2013; Xiao et al. 2016) and their non-toxic
properties were tested by viability assays (data not
shown).
NRK-49F cells were treated with PDGF (10 ng mL−1)
or CTGF/CCN2 (10 ng mL−1) and with various RAASi
as described above. In pilot studies the most effective
proliferative doses were determined from different PDGF
and CTGF/CCN2 concentration series by proliferative
assays (data not shown). Cells were subsequently
incubated at 5% CO2 and 37°C, detached with 0.25%
trypsin-EDTA (Gibco) and lysed with the same buffers
that were used for kidney homogenates.
Todifferentiate between the effect of direct glucotoxicity
and the osmotic effect of high glucose (HG), HK-2 cells
were cultured in normal (5.5mM) orHG (35mM)media,
aswell as in isosmotic controlmannitol (5.5mMglucose+
29.5 mMmannitol).
Biomarkers of ECM formation and degradation
The biomarkers uC3M (measuring collagen type III
fragment degraded by MMP-9), rPRO-C3 (measuring
type III collagen formation) and TUM (measuring
tumstatin, a collagen type IV fragment degraded by
MMP-9) were measured in rat urine samples. FBN-C
(measuring C-terminal of fibronectin turnover) and
PRO-C4 (measuring type IV collagen formation) were
measured inHK-2 andNRK-49F cell supernatant samples,
using competitive enzyme-linked immunosorbent assays
(ELISAs) developed by Nordic Bioscience (Herlev,
Denmark). To normalize for urine output, levels were
divided by urinary creatinine levels measured with the
QuantiChromTM Creatinine kit (BioAssay Systems). The
assays were carried out at Nordic Bioscience laboratories
following previously described protocols (Leeming et al.
2013; Nielsen et al. 2013, 2018; Bager et al. 2016; Genovese
et al. 2016). Briefly, astreptavidin-coated 96-well ELISA
plates (Roche,Cat.No. 11940279)were coatedwith100μL
biotinylated peptide for 30 min at 20°C. Plates were
washedfive times inwashingbuffer followedby incubation
with 20 μL standard peptide or sample together with
HRP-conjugated monoclonal antibody and incubated for
20 h at 4°C (uC3M, rPRO-C3, FBN-C) or 1 h at 20°C
(TUM, PRO-C4). Plates were washed five times followed
by incubation with 100 μL 3,3ʹ,5,5-tetramethylbenzidine
(Kem-En-Tec, Cat. No. 4380H, Taastrup, Denmark) for
15 min at 20°C in the dark. To stop the reaction, 1%
sulfuric acid solution was added, and plates were analysed
with the ELISA reader at 450 nM,with 650 nm as reference
(VersaMax, Molecular Devices, CA, USA).
Fluorescent immunohistochemistry
Frozen kidney sections were embedded in Shandon
cryomatrix (Thermo Fisher Scientific, Waltham, MA,
USA) and cut into 10-μm slices with a cryostat.
NRK-49F cells were cultured in tissue culture chambers.
After repeated washes with PBS, cells were fixed in
4% formalin, washed again, and permeabilised with
Triton X-100. Samples were incubated for 2 h with
specific primary antibodies: anti-αSMA (Sigma-Aldrich,
Cat. No. A2547, RRID:AB 476701) diluted 1:1000
or anti-PDGFR-β (Santa Cruz Biotechnology, Cat.
No. sc-432, RRID:AB 631068) diluted 1:100. After
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repeated washes, slides were incubated with specific
secondary antibodies: goat anti-mouse IgG Alexa fluor
488 (Thermo Fisher Scientific, Cat. No. A-11001,
RRID:AB 2534069) diluted 1:100 or goat anti-rabbit
Alexa fluor 568 (Thermo Fisher Scientific, Cat. No.
A-11036, RRID:AB 10563566) diluted 1:100. F-actin was
immunostained by incubation with phalloidin-TRITC
diluted 1:300 for 1 h at room temperature. Samples
were counterstained with Hoechst 33342 (Cell Signaling
Technology, Cat. No. 4082S, RRID:AB 10626776) diluted
1:1000 to visualise nuclei. Appropriate controls were pre-
pared omitting the primary antibody to assure specificity
and to avoid autofluorescence. After being dried, sections
were fixed with Vectashield Mounting Medium (Vector
Laboratories, Cat. No. H-1000, RRID:AB 2336789).
Coverslipped slides were analysed with a Zeiss LSM
510 Meta confocal laser scanning microscope (LSM
Image Examiner, RRID:SCR 014344) with 63× or 100×
magnification objectives or, for phalloidin-stained slides,
with an Olympus IX81 fluorescence microscope at 100×
magnification.
Western blot analysis
Kidney cortex samples or cells were homogenised in
lysis buffer (1 M Tris, 0.5 M EGTA, 1% Triton X-100,
0.25 M NaF, 0.5 M phenylmethylsulfonyl fluoride,
0.5 M sodium orthovanadate, 5 mg mL−1 leupeptin,
and 1.7 mg mL−1 aprotinin, pH 7.4). Lysates were
centrifuged at 13,000 rpm, at 4°C for 10 min. Protein
concentration of the supernatants was measured with a
detergent-compatible protein assay kit (Bio-RadHungary,
Budapest, Hungary). Solubilised samples were electro-
phoretically resolved: appropriate amounts (25 μg
for tissue and 18 μg for cells) of protein were
loaded onto 4–20% gradient Mini-PROTEAN TGX
polyacrylamide precast gels (Bio-Rad Hungary) and
transferred to nitrocellulose membranes. Membranes
were blocked in 5% w/v non-fat dried milk in
Tris-buffered saline (TBS) for 1 h at room temperature
and incubated with primary antibody anti-αSMA
(Sigma-Aldrich, Cat. No. A2547, RRID:AB 476701)
diluted 1:2000 at 4°C overnight. After washing with
1% w/v non-fat dried milk in TBS-Tween, membranes
were incubated with the appropriate HRP-conjugated
secondary antibody goat anti-mouse IgG (Cell Signaling
Technology, Cat. No. 7076, RRID:AB 330924) diluted
1:6000. Antibody-antigen complexes were detected using
enhanced chemiluminescence (ECL by GE Healthcare
Life Sciences, Budapest, Hungary) and immunoreactive
bands were quantified densitometrically on Versadoc,
Quantity One 1-D Analysis software (Bio-Rad Hungary,
RRID:SCR 01428) as integrated optical density (IOD)
after subtraction of background. The IOD was factored
for Ponceau S staining to correct for any variations in total
protein loading. The protein abundance was represented
as IOD/Ponceau S/Internal control.
Reverse transcription polymerase chain reaction
(RT-PCR)
Total RNA was extracted using the RT050 Total RNA
isolation Mini Kit (Geneaid Biotech, New Taipei City,
Taiwan). The quality and quantity of isolated RNA was
measured on a NanoDrop ND-1000 spectrophotometer
(Baylor College of Medicine, Houston, TX, USA). Five
hundred nanograms each of Tgfb1, Pdgfb, Ctgf, Mmp2,
Timp1, Timp2mRNA from rat kidney samples and 500 ng
each of TGFB1, PDGFB and CTGF mRNA from human
proximal tubular epithelial cells were reverse-transcribed
using a First Strand cDNA Synthesis Kit for RT-PCR
(Thermo Fisher Scientific). The expression of the
mRNAs was determined in triplicate with 1 μL cDNA
samples obtained by qPCR using 10 μL SYBR Green
I Master enzyme mix (Roche Diagnostics, Mannheim,
Germany) and 10 pmol μL−1 of each specific primer
(Invitrogen, Budapest, Hungary), following sequences
designed by Lasergene PrimerSelect software version 7.1.0
(DNASTAR, RRID:SCR 016295) based on nucleotide
sequences from National Center for Biotechnology
Information’s nucleotide database (primer sequences:
Table 1). Resultswere analysedbyLightCycler 480 software
version 1.5.0 (Roche Diagnostics, RRID:SCR 012155).
The mRNA expression of interest was normalised against
mRNA expression of 18S ribosomal RNA (Rn18s or
RN18S) from the same samples as internal control.
Statistical analysis
To test the hypothesis that RAAS inhibition plays a
renoprotective antifibrotic role in the rat model of
STZ-induced DKD, statistical analyses were performed
using GraphPad Prism software version 6.01 (GraphPad
Software, RRID:SCR 002798). To test if the values
were from a Gaussian distribution, a Kolmogorov-
Smirnov normality test was performed. Data were
analysed by one-way ANOVA followed by Bonferroni’s
multiple-comparison post hoc test for all parametrical
comparisons, or in the case of non-parametric data, by
Kruskal-Wallis ANOVA on ranks. Significance was set a
priori at P < 0.05, corrected for multiple comparisons.
Data are presentedusingbox andwhisker plotswithmeans
and 95% confidence intervals.
Results
RAAS inhibitors improve metabolic and renal
functional parameters in STZ-induced diabetic rats
Elevated serum glucose, fructosamine levels and lower
body weights confirmed the development of type 1
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Table 1. PCR primer sequences used in this study
Gene
name Regular name NCBI ID Primer pairs
Product
lenght Ta
Tgfb1 Rat TGFβ1 21803 Forward: 5ʹ-GCA CCG GAG AGC CCT GGA TAC C-3ʹ 222 bp 60°C
Reverse: 5ʹ-CCC GGG TTG TGT TGG TTG TAG AGG-3ʹ
Pdgfb Rat PDGFB 24628 Forward: 5ʹ-TCG ATC GCA CCA ATG CCA ACT TCC-3ʹ 236 bp 62°C
Reverse: 5ʹ-CAC GGG CCG AGG GGT CAC TAC TGT-3ʹ
Ctgf Rat CTGF 64032 Forward: 5ʹ-TCC ACC CGG GTT ACC AAT GAC AAT AC-3ʹ 195 bp 58°C
Reverse: 5ʹ-CTT AGC CCG GTA GGT CTT CAC ACT GG-3ʹ
Mmp2 Rat MMP2 81686 Forward: 5ʹ-TCC CCC AAA ACA GAC AAA GAG T-3ʹ 224 bp 56°C
Reverse: 5ʹ-TTG CGG GGA AAG AAG TTG TAG T-3ʹ
Timp1 Rat TIMP1 116510 Forward: 5ʹ-GGC GCC CTT TGC ATC TCT GG-3ʹ 250 bp 58°C
Reverse: 5ʹ-GGC GAA CCG GAA ACC TGT GG-3ʹ
Timp2 Rat TIMP2 29543 Forward: 5ʹ-GCC CTG GGA CAC GCT TAG CAT C-3ʹ 220 bp 59°C
Reverse: 5ʹ-GTA CCA CGC GCA AGA ACC ATC ACT-3ʹ
Rn18s Rat 18S ribosomal
RNA
100861533 Forward: 5ʹ-GCG GTC GGC GTC CCC CAA CTT CTT-3ʹ 105 bp 60°C
Reverse: 5ʹ-GCG CGT GCA GCC CCG GAC ATC TA-3ʹ
TGFB1 Human TGFβ1 7040 Forward: 5ʹ-GCG TGC GGC AGC TGT ACA TTG ACT-3ʹ 174 bp 60°C
Reverse: 5ʹ-CGA AGG CGC CCG GGT TAT GC-3ʹ
PDGFB Human PDGFB 5155 Forward: 5ʹ-AGA TGG GGC CGA GTT GGA CCT GAA-3ʹ 163 bp 62°C
Reverse: 5ʹ-GCG CCG GGA GAT CTC GAA CAC CT-3ʹ
CTGF Human CTGF 1490 Forward: 5ʹ-GTC CAC CCG GGT TAC CAA TGA CAA-3ʹ 228 bp 58°C
Reverse: 5ʹ-CAG GAT CGG CCG TCG GTA CAT ACT-3ʹ
RN18S Human 18S
ribosomal RNA
HQ387008.1 Forward: 5ʹ-CGC GGA TCC GAA CAC TGC GTT TGC TGG
CTT TGA TG-3ʹ
136 bp 60°C
Ta, annealing temperature.
Table 2. Bodyweight, metabolic parameters andmean arterial pressure (MAP) of control, diabetic and renin-angiotensin-aldosterone
system inhibitor-treated diabetic rats
Parameters Control Diabetes (D) D + ramipril D + losartan D + spironolactone D + eplerenone
Body weight (g) 418 ± 23.4 276 ± 28.9∗ 265 ± 12.8∗ 258 ± 24.8∗ 245 ± 35.1∗ 288 ± 20.9∗
Serum glucose
(mmol L−1)
12.7 ± 1.15 47.3 ± 7.80∗ 44.1 ± 3.67∗ 43.8 ± 4.79∗ 42.6 ± 2.55∗ 34.8 ± 3.57
Serum fructosamine
(μmol L−1)
153 ± 8.28 243 ± 16.3∗∗∗ 249 ± 10.6∗∗∗ 256 ± 17.6∗∗∗ 239 ± 11.5∗∗∗ 239 ± 16.5∗∗∗
MAP (mmHg) 74.7 ± 7.51 73.9 ± 8.78 72.3 ± 5.46 73.8 ± 14.0 77.4 ± 16.0 77.3 ± 13.2
Values are presented as means ± 95% confidence limits; n = 7–8 rats/group; one-way ANOVA followed by Bonferroniʹs
multiple-comparison post hoc test; ∗P < 0.05, ∗∗∗P < 0.001 vs. control.
diabetesmellitus. RAASi did not alter any of themetabolic
parameters. Mean arterial pressure remained unaltered in
all groups confirming that the examined effects of RAASi
are independent of their antihypertensive properties
(Table 2). A decline in renal functional parameters
and higher kidney-to-body weight ratios indicate the
development of DKD. RAASi reduced relative kidney
enlargement, improved creatinine clearance anddecreased
renal retention parameters (Fig. 1A). Urinary biomarkers
of ECM remodelling showed increased collagen III
formation (rPRO-C3) and degradation (uC3M) and
collagen IV turnover (TUM) in diabetic animals.
Eplerenone treatment decreased the level of uC3M level
(Fig. 1B). Besides functional decline, a key histological
features of DKD, massive glomerular hypertrophy and
mesangial matrix expansion were observed in untreated
diabetic rats. All of the RAASi minimised structural
damage as reflected by smaller PAS positive glomerular
areas (Fig. 1C).
RAAS inhibitors ameliorate tubulointerstitial fibrosis
in diabetic kidneys
Renal tubulointerstitial fibrosis was assessed on Masson’s
trichrome-stained sections. The quantity of fibrotic
connective tissue increased in diabetic animals, while
all of the RAASi decreased tubulointerstitial fibrosis
(Fig. 2A). To assess accumulation of the collagen
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 597.1 Renal fibrosis in diabetic kidney disease is reduced by RAASi 199
Figure 1. Renal functional parameters, kidney histology and urinary fibrotic markers of control, diabetic
and renin-angiotensin-aldosterone system inhibitor-treated diabetic rats
A, kidney-to-body weight ratio, creatinine clearance, serum creatinine, and blood urea nitrogen were measured
in rats. B, urinary collagen type III degradation fragment (uC3M), tumstatin (TUM) and N-terminal pro-peptide of
rodent type III collagen (rPRO-C3) levels measured from rat urine. C, representative periodic acid-Schiff (PAS)-stained
histological sections and quantitative evaluation of glomerular hypertrophy and mesangial matrix expansion.
Arrows mark mesangial matrix deposition stained with purple. 400× magnification; scale bar = 50 μm. Values are
presented as means ± 95% confidence intervals; n = 7–8 rats/group; one-way ANOVA followed by Bonferroniʹs
multiple-comparison post hoc test; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. control; #P = 0.08, §P < 0.05,
§§P < 0.01, §§§P < 0.001 vs. D.
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Figure 2. Fibrotic alterations in
kidneys of control, diabetic and
renin-angiotensin-aldosterone system
inhibitor treated diabetic rats
A, representative Massonʹs
trichrome-stained histological sections and
quantitative evaluation of renal
tubulointerstitial fibrosis by
Masson-positive and glomerulus-free vs.
total areas in the kidney cortex. Arrows
mark fibrotic tissue stained with blue.
200× magnification; scale bar = 100 μm.
B, representative Picrosirius Red-stained
histological kidney sections and
quantitative evaluation of collagen
accumulation. Arrows mark red-stained
collagen. 100× magnification; scale bar =
200 μm. On each graph values are
presented as means ± 95% confidence
intervals; n = 7–8 rats/group;
Kruskal-Wallis ANOVA on ranks; ∗∗∗P <
0.001 vs. control; §§§P < 0.001 vs. D. C,
representative fluorescent
immunohistochemical staining of renal
sections and Western blot analysis of
alpha-smooth muscle actin (αSMA)
protein levels in the kidneys, with
representative examples above. Samples
might be from different gels but were
derived at the same time and processed in
parallel. 630× magnification; green,
αSMA; blue, nucleus; scale bar = 20 μm;
values are presented as means ± 95%
confidence intervals; n = 7–8 rats/group;
one-way ANOVA followed by Bonferroniʹs
multiple-comparison post hoc test;
∗∗∗P < 0.001 vs. control; §§§P < 0.001
vs. D.
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components of ECM, Picrosirius Red staining was
performed, which showed increased amounts of collagen
in diabetic kidneys. RAASi also significantly decreased
renal collagen depositions (Fig. 2B). Another widely
accepted important and specific marker of fibrosis
is the increased level of αSMA, which indicates the
activation and differentiation of fibroblasts (Skalli et al.
1987). We demonstrated that in diabetic animals, the
level of αSMA is significantly increased and the protein
is mainly localised in the tubulointerstitial region.
RAASi decreased the accumulation of αSMA protein
(Fig. 2C).
Aldosterone antagonists decrease PDGF
and CTGF/CCN2 levels in diabetic kidneys
Since DKD-associated cytokines induce fibrotic
differentiation (Boor & Floege, 2011), we measured
Tgfb1, Pdgfb and Ctgf mRNA expression in the renal
cortex. In the diabetic group, expression of all profibrotic
factors was elevated. RAASi did not alterTgfb1 expression,
while aldosterone antagonists decreased Pdgfb and Ctgf
expression (Fig. 3A).
Matrix metalloproteinases facilitate ECM turnover and
serve as a marker of renal fibrosis (Du et al. 2012). In
diabetic rats renal Mmp2 expression was increased, and
aldosterone antagonists showed the most robust effect in
minimizing Mmp2 expression. Expression of the tissue
inhibitor of matrix metalloproteinase 1 (Timp1) also
increased in diabetes, following the increase in Mmp2.
This changewas also alleviated by losartan and eplerenone
treatment (Fig. 3B). The expression of Timp2 and Mmp9
remained the same in all groups (data not shown).
RAAS inhibitors prevent PDGF and CTGF/CCN2
production in HK-2 proximal tubular epithelial cells
In vitro experiments were performed to further clarify
the profibrotic signal transduction pathways. HK-2 cells
were cultured both in normal, HG or mannitol-treated
isosmotic conditions to distinguish the per se effects of
hyperosmolality and hyperglycaemia on proximal tubule
Figure 3. mRNA expression of profibrotic factors and fibrotic marker extracellular matrix enzymes in
control, diabetic and renin-angiotensin-aldosterone system inhibitor-treated diabetic rats
A, transforming growth factor β 1 (Tgfb1), platelet-derived growth factor B (Pdgfb) and connective tissue growth
factor (Ctgf) mRNA expression measured in kidney. B, matrix metalloproteinase 2 (Mmp2) and tissue inhibitor of
matrix metalloproteinase 1 (Timp1) mRNA expression measured in kidney. Values are presented as means ± 95%
confidence intervals; n = 7–8 rats/group; one-way ANOVA followed by Bonferroniʹs multiple-comparison post hoc
test; ∗P < 0.05, ∗∗P < 0.01 vs. control; §P < 0.05, §§P < 0.01, §§§P < 0.001 vs. D.
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cells. Expression of TGFB1, PDGFB and CTGF was
increased in HG-treated HK-2 cells. TGFB1 and PDGFB
expression did not change with mannitol treatment, but,
in contrast, mannitol enhanced CTGFmRNA expression.
These results suggest that the elevation of TGFB1 and
PDGFB canbe considered as a direct effect of glucotoxicity,
while CTGF production is the result of the complex effect
of hyperglycaemia and hyperosmolarity (Fig. 4A).
RAASi significantly reduced elevated expression of both
PDGFB and CTGF to the level of controls (Fig. 4B). Since
RAASi did not influence TGFB1 expression either in the
kidney or in HK-2 cells, we focused our further analyses
on PDGFB and CTGF.
RAAS inhibitors restore normal fibronectin turnover
in HK-2 proximal tubular epithelial cells
The amount of C-terminal of fibronectin (FBN-C)
secreted into the supernatant is a biomarker of fibronectin
turnover. High glucose treatment reduced the level of
FBN-C (fibronectin turnover), which was restored to
the level of controls by treatment with spironolactone
and eplerenone (Fig. 5A). Secreted FBN-C levels in
NRK cells were below the lower limit of detection. The
amount of internal epitope in the 7S domain of type IV
collagen (PRO-C4) secreted into the cells’ supernatant
serves as a collagen formation biomarker. No changes in
type IV collagen formation in HK-2 cells (Fig. 5B) and
NRK-49F cells (Fig. 5C andD) were detected in any of the
goups.
PDGF and CTGF/CCN2-induced αSMA production
of renal fibroblasts is prevented by RAAS inhibitor
treatment
Since the profibrotic factors produced by proximal tubular
epithelial cells act directly on the renal fibroblasts, the
effect of PDGF and CTGF/CCN2 treatment on αSMA
production of NRK-49F cells was also evaluated.
Using fluorescent immunohistochemistry, we firstly
proved that NRK-49F cells express PDGF receptor β
(PDGFR-β) (Fig. 6A), which is essential for the action
Figure 4. Profibrotic factor production in human kidney 2 (HK-2) cells on normal, high glucose (HG),
mannitol and renin-angiotensin-aldosterone system inhibitor (RAASi) treatment
A, transforming growth factor β (TGFB1), platelet-derived growth factor B (PDGFB), and connective
tissue growth factor (CTGF) mRNA expression in HK-2 proximal tubular epithelial cells on HG or
osmotic control mannitol treatment. B, TGFB1, PDGFB, and CTGF mRNA expression in HK-2 cells
on HG and RAASi treatment. Values are presented as means ± 95% confidence intervals; n = 6
wells/group; one-way ANOVA followed by Bonferroniʹs multiple-comparison post hoc test; ∗P < 0.05,
∗∗∗P < 0.001 vs. control; §P < 0.05, NS, not significant vs. HG
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of both PDGF and CTGF/CCN2. Morphological changes
on NRK-49F cells caused by PDGF and CTGF treatments
were visualised by immunostaining of F-actin with
phalloidin-TRITC. Control cells had a slightly elongated
shape and a diffuse actin network of thin actin filaments
(Fig. 6B) PDGF and CTGF/CCN2 treatments induced
actin cytoskeleton rearrangement in NRK-49F cells. The
elongation of cells was caused by the reorganization of
stress fibres along a longitudinal axis, with the formation
of F-actin bundles. Both treatments caused formation of
actin-clumps, especially at the edges of fibroblasts (Fig. 6C
and D).
Secondly, we showed that PDGFB and CTGF/CCN2
treatments increased αSMA protein levels in renal
fibroblasts, indicating fibroproliferative activation and
differentiation ofNRK-49F cells. All RAASi hindered these
changes, by restoringαSMA to the level of controls (Fig. 6E
and F).
Discussion
The frequencyofDMis enormously increasingworldwide,
thus more and more people are exposed to the risk of
developing diabetic complications. DKD is one of the
Figure 5. Extracellular matrix formation and degradation biomarkers measured in human kidney 2
(HK-2) cells on high glucose (HG) and renin-angiotensin-aldosterone system inhibitor (RAASi) treatment
and in normal rat kidney fibroblast (NRK-49F) cells treated with profibrotic factors and RAASi
A, C-terminal of fibronectin (FBN-C) turnover marker secretion by HK-2 proximal tubular epithelial cells on HG
and RAASi treatment. B, type IV collagen formation biomarker (PRO-C4) secretion by HK-2 cells on HG and RAASi
treatment. C and D, PRO-C4 secretion by NRK-49F cells treated with platelet-derived growth factor (PDGF; C) or
connective tissue growth factor (CTGF; D). Values are presented as means ± 95% confidence intervals; n = 6
wells/group; one-way ANOVA followed by Bonferroniʹs multiple-comparison post hoc test; ∗P < 0.05 vs. control;
§§P < 0.01 vs. HG.
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most detrimental consequences of DM regarding patients’
quality of life and survival (Trikkalinou et al. 2017).
Therefore, there is a great demand for new therapies
to slow down the progression of DKD and deepen our
understanding of the molecular mechanisms involved.
The primary goal of our study was to evaluate the mono-
therapeutic effect of different RAASi as protection against
DM-induced kidney fibrosis.
DKD is a complex disease, characterised by several
pathophysiological changes including glomerular hyper-
trophy with progressive mesangial expansion, and
tubulointerstitial fibrosis. Besides hypertension, hyper-
glycaemia is also a major contributing factor, and both
effects activate local renal RAAS, subsequently increasing
intraglomerular pressure, cellular growth, and fibroblast
differentiation (Macia-Heras et al. 2012).
RAASi are the standard treatments in the care for
hypertensive patients with DM, especially when renal
involvement is present (American Diabetes Association,
2018). Their ability to lower blood pressure has been well
documented, but they also reduce kidney and glomerular
hypertrophy, and renal inflammation without affecting
blood pressure (Kobori et al. 2013). The antifibrotic
potential of angiotensin II receptor 2 agonism (Morrissey
& Klahr, 1999), and AT1 antagonism (Gross et al. 2004),
as well as ACE inhibition (Rubel et al. 2014), has been
already explored in murine models of unilateral ureteral
obstruction and progressive renal fibrosis. Furthermore,
RAASi have already been shown to reduce renal fibrosis in
DKD (Liao et al. 2003; Han et al. 2006; Feldman et al.
2008), but the complexity of the exact mechanisms is
still not fully clarified. To test whether the antifibrotic
properties of RAASi are associated with or restricted to
their antihypertensive effect, we chose lower treatment
dosages avoiding blood pressure changes. In the present
study neither diabetes nor RAASi affected blood pressure,
which confirms the non-depressor doses of drugs used in
our protocol.
Figure 6. Effect of profibrotic factors and renin-angiotensin-aldosterone system inhibitors (RAASi) on
normal rat kidney fibroblast (NRK-49F) cells
A, representative picture of platelet-derived growth factor receptor β (PDGFR-β) stained NRK-49F cells. 1000×
magnification; red, PDGFRβ; blue, nucleus; scale bar = 20 μm. B–D, representative pictures of phalloidin-TRITC
immunostained NRK-49F cells (control, B) treated with platelet-derived growth factor (PDGF; C) or connective
tissue growth factor (CTGF/CCN2; D). 1000× magnification; red, F-actin; blue, nucleus; scale bar = 20 μm. E and
F, alpha-smooth muscle actin (αSMA) protein levels in NRK-49F cells treated with PDGF (E) or CTGF/CCN2r (F) and
RAASi. Representative gel image examples shown above the panels. Samples might be from different gels but
were derived at the same time and processed in parallel. On each graph values are presented as means ± 95%
confidence intervals; n = 6 wells/group; one-way ANOVA followed by Bonferroniʹs multiple-comparison post hoc
test; ∗P < 0.05, ∗∗∗P < 0.001 vs. control; §P < 0.05, §§§P < 0.001 vs. PDGF or CTGF.
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In line with our previous studies, we also observed
severe structural and functional kidney damage in diabetic
animals, which was improved by all RAASi (Banki et al.
2012). According to the literature and our previous results,
this renoprotectiongoesbeyonddecreasingbloodpressure
and can be related to other factors like lower oxidative
stress (Fiordaliso et al. 2006) or O-GlcNAc levels (Gellai
et al. 2016).
Overexpression of profibrotic factors such as TGFβ,
CTGF/CCN2 and PDGF has been implicated in the
development of DKD through the modulation of various
signal transduction pathways and renal structural changes
(Wang et al. 2015). They contribute to the fibrotic process
by enabling fibroblasts to differentiate andmigrate, which
eventually induces the expression of ECM components
including collagen type III and MMP9 (Powell et al.
1999). In the present study, we demonstrated that mono-
therapy with various RAASi successfully regulates the
hyperglycaemia-induced fibrotic response and supresses
the level of profibrotic factors both in vivo and in vitro.
To the best of our knowledge, this is the first study
to use ECM remodelling biomarkers to test the efficacy
of treatment of fibrosis in diabetes. These measurements
non-invasively provide relevant information on renal
fibrotic processes and correlate with histological findings.
Here we observed that eplerenone could reduce the
urinary levels of a biomarker of collagen type III
turnover that was highly upregulated in diabetic rats.
Aldosterone antagonists restored the biomarker of
fibronectin turnover secreted into the supernatant to
control levels, which confirmed a decrease in fibronectin
turnover in HG-treated HK-2 cells. These observations
suggest a role for RAASi that involves interfering with
the dysregulated remodelling of the interstitial ECM that
characterizes fibrosis.
TGFβ1 is one of the three isoforms of TGFβ and it
is the most commonly studied profibrotic growth factor.
Its relevance has been emphasised in both normal tissue
repair (Kane et al. 1991) and in the development of
several fibrotic processes. It promotes ECM deposition by
inducing fibroblasts to differentiate and synthesise fibrotic
components (Leask & Abraham, 2004). The expression of
TGFB1 was found to be elevated in human experimental
diabetic kidney diseases (Yamamoto et al. 1993).
In line with these studies we showed that Tgfb1/TGFB1
mRNA expression was increased in the kidney of diabetic
rats, and also in HG-treated HK-2 cells. This increment
can be considered an effect of glucotoxicity, rather
than hyperglycaemia-induced hyperosmolarity, since the
TGFB1 level was not increased by the isosmotic control
mannitol treatment.
The connection between TGFβ and RAAS inhibition in
STZ-diabetes has been discussed in only a few studies so
far. These showed that someRAASi attenuate renalTGFβ1
expression in STZ-diabetic rats, although in these studies
valsartan (Huang et al. 2011), and aliskiren (Feldman et al.
2008) treatments were initiated from the beginning of the
diabetes and the drugs were administered directly into
the renal cortex or subcutaneously, but not orally. Other
studies in which RAASi successfully affected TGFβ1 levels
have been conducted on other kidney disease models such
as the subtotal nephrectomy model (Piecha et al. 2008),
and used different type of RAASi (Liao et al. 2003). Inter-
estingly, in our study, per os RAASi had no effect on Tgfb1
expression either in the diabetic rat kidney, or in HK-2
cells. Therefore, it appears that Tgfb1 reduction is not one
of the antifibrotic mechanisms by which RAASi act in the
advanced stage of DKD in STZ rats.
The expression of other profibrotic factors like PDGF
and CTGF can be activated through TGFβ-dependent and
-independent pathways (Yang et al. 2009). Both factors
can act through PDGFR-β (Makino et al. 2017), which is
widely distributed throughout the cytoplasmof fibroblasts
(Huang & Huang, 1988), as we also detected in our study.
PDGF consists of homo- and heterodimers and
PDGF-BB is crucial for production and maintenance
of renal structures and ECM (Ostendorf et al. 2012).
PDGF is also involved in structural alterations of
DKD. Di Paolo et al. (1996) demonstrated that HG
induced a persistent increase in PDGFB expression,
thus stimulating fibroblast proliferation, collagen and
ECM production. Ramipril, eplerenon, irbesartan and
spironolactone decreased PDGFB in experimental hepatic
(Li et al. 2005), myocardial (Nishioka et al. 2007) and
atrial fibrosis (Yang et al. 2013) and in cyclosporine
nephrotoxicity (Macunluoglu et al. 2008). To the best of
our knowledge the effect of RAASi on PDGFB has not yet
been investigated in DKD.
CTGF/CCN2 is a matricellular protein that promotes
angiogenesis, inflammation, tissue repair and fibrosis
(Lipson et al. 2012). Overexpression of CTGF is now
widely accepted as a key marker of fibrotic activity. In
diabetic kidneys the expression level ofCTGF in the kidney
is increased (Wang et al. 2001), and high glucose levels
were also identified as an in vitro stimulus (Murphy et al.
1999). Losartan and spironolactone have been shown to
decrease CTGF/CCN2 in human (Andersen et al. 2005)
and experimental DKD (Han et al. 2006).
In agreement with earlier reports both in the diabetic
kidneys (Floege et al. 2008), as well as in HG-cultured
HK-2 cells (Mesarosova et al. 2017), we found higher
PDGFB and CTGF expression in our rat model. RAASi
decreased the production of both growth factors and
also diminished their expression when administered to
renal proximal tubular cells, suggesting that these drugs
directly act on proximal tubules by inhibitingHG-induced
upregulation of the profibrotic PDGFB and CTGF genes,
but surprisingly not the TGFB1 gene.
As we treated NRK fibroblasts with either PDGF
or CTGF/CCN2, morphological changes showed actin
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cytoskeleton rearrangement. Similar transformations
have been described in human fibroblasts (Hedberg et al.
1993), and smooth muscle cells (Kuzuya et al. 2004) due
to PDGF treatment; and in podocytes (Fuchshofer et al.
2011) after CTGF/CCN2 administration. Furthermore, in
our experiments the production of αSMA also increased,
indicating myofibroblast differentiation. We showed
for the first time that all the RAASi tested successfully
decreased this fibrotic transformation, indicating that
these cells might be one of the primary targets of
RAASi.
MMP2 is an endopeptidase responsible for the
degradation of the major components of ECM proteins,
and thus it has an important role in senescence and
fibrosis. The renal expression of Mmp2 was shown to
increase as a compensatory mechanism in STZ-induced
DKD (Takamiya et al. 2013), as we also observed in the
present study. In renal cortex of diabetic rats, higherMmp2
expression was decreased by RAASi, most successfully
by aldosterone ant agonists. TIMP1 is an endogenous
inhibitorofMMPswhich influencesECMintegrity and the
tissuemicroenvironment. Its expressionwas also increased
in the kidneys of diabetic rats, indicating that fibrosis
increased because ECM degradation was restricted, and
RAASi treatments prevented TIMP1 production.
In summary, we describe here a novel molecular
mechanism by which RAASi are effective in the pre-
vention of hyperglycaemia-induced fibrosis. We showed
that RAASi directly target renal proximal tubular cells by
reducing PDGFB and CTGF, but not TGFβ1 production,
and also inhibitαSMAaccumulation in kidney fibroblasts.
Ours is the first study to compare different RAASi and
suggest that monotherapy with aldosterone antagonists
might be as effective as, or even more effective than ACE
inhibitors or angiotensin II receptor blockers inpreventing
the progression of renal fibrosis in DKD.
In conclusion, the present study demonstrates that
RAASi drugs in monotherapy are effective at supporting
kidney function and preventing renal fibrosis in STZ-
induced DKD. We suggest that alteration of profibrotic
factor production and fibroblast differentiation might
serve as an additional target of RAASi and could
facilitate their monotherapeutic application in the clinical
management of renal fibrosis. A better understanding of
these targets could facilitate the development of novel
therapeutic strategies translated into clinical applications,
but well-controlled human clinical trials are needed
to confirm these suggestions and to evaluate of the
risk/benefit ratio, especially of aldosterone antagonists.
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Translational perspective
Diabetic kidney disease (DKD) is the leading cause of end stage renal disease, where the increased
activation of the renin-angiotensin-aldosterone system (RAAS) contributes to renal fibrosis. We
investigated the effect of hyperglycaemia on the development of fibrosis and its signal-transduction
pathway in vivo and in vitro, and examined the possible antifibrotic effect of RAAS inhibitors (RAASi).
In the present study we report that in type 1 diabetic rats renal interstitial fibrosis was ameliorated,
while elevated profibrotic factor levels were decreased by RAASi. Hyperglycaemia-induced profibrotic
factor production in proximal tubular epithelial cells increases fibroblast activation, both of which
effects can be prevented with RAASi treatment. These results can help establish new therapeutic
possibilities for the treatment of DKD and facilitate the monotherapeutic application of aldosterone
antagonists. This animal study provides a basis for future clinical trials of the antifibrotic potential
of RAASi treatment. Such studies may further reveal the mechanisms underlying the pleiotropic
renoprotective effect of RAASi.
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